Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Yuzuru Kanakura is active.

Publication


Featured researches published by Yuzuru Kanakura.


Leukemia | 1992

Simultaneous administration of granulocyte-macrophage colony-stimulating factor and cytosine arabinoside for the treatment of relapsed acute myeloid leukemia.

Stephen A. Cannistra; Jennifer DiCarlo; P Groshek; Yuzuru Kanakura; D. Berg; Robert J. Mayer; James D. Griffin

The treatment of patients with relapsed or refractory acute myeloid leukemia (AML) with high dose cytosine arabinoside (ara-C) results in short-lived complete response rates of 30-50%. We have previously shown that entry of myeloid leukemic cells into S phase can be accelerated in vitro through the use of recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF), resulting in enhancement of ara-C-mediated cytotoxicity. In order to evaluate the in vivo biological and clinical effects of this strategy in patients with high risk AML, we treated three patients with either refractory or relapsed disease with a continuous infusion of rhGM-CSF (0.45 micrograms/kg/h aglycoprotein) for 18 h, followed by the institution of high dose ara-C and continuation of rhGM-CSF throughout the 4 day duration of ara-C treatment. Prior to therapy, no patient had detectable levels of circulating rhGM-CSF, and there was no evidence of GM-CSF receptor occupancy in leukemic myeloblasts. After 18 h of rhGM-CSF therapy, all patients had biologically active levels of circulating rhGM-CSF (7.9-12.0 ng/ml), and two patients showed a significant degree of leukemic GM-CSF receptor occupancy without evidence of GM-CSF receptor down-regulation. A significant rise in the S phase fraction of leukemic myeloblasts was observed at 18 h of rhGM-CSF treatment in all three patients (29-56% increment). The toxicity of combined rhGM-CSF/ara-C therapy included pericarditis and cerebellar degeneration in one patient, fever and mild renal dysfunction in two patients, and mild hepatic dysfunction in all three patients. Each patient showed a transient rise in the absolute neutrophil and blast count during rhGM-CSF/ara-C administration, followed by profound, but clinically tolerable, myelosuppression. No patient developed clinical evidence of leukostasis. There was one death related to pericardial tamponade, one death related to refractory disease, and one clinical and cytogenetic remission. These results suggest that exogenously administered rhGM-CSF is capable of rapidly mobilizing leukemic cells into S phase in vivo and theoretically should be useful in overcoming kinetic resistance to ara-C. Clinical trials of this regimen in patients with high risk AML who are not already pharmacologically resistant to ara-C are warranted.


Journal of Immunology | 1990

Granulocyte-macrophage colony-stimulating factor and other cytokines regulate surface expression of the leukocyte adhesion molecule-1 on human neutrophils, monocytes, and their precursors.

James D. Griffin; Olivier Spertini; Timothy J. Ernst; M. P. Belvin; H Levine; Yuzuru Kanakura; Thomas F. Tedder


Blood | 1990

Signal transduction of the human granulocyte-macrophage colony- stimulating factor and interleukin-3 receptors involves tyrosine phosphorylation of a common set of cytoplasmic proteins

Yuzuru Kanakura; Brian J. Druker; Stephen A. Cannistra; Yusuke Furukawa; Y Torimoto; James D. Griffin


Science | 1990

cdc2 gene expression at the G1 to S transition in human T lymphocytes

Yusuke Furukawa; Helen Piwnica-Worms; Timothy J. Ernst; Yuzuru Kanakura; James D. Griffin


Proceedings of the National Academy of Sciences of the United States of America | 1990

Expression and state of phosphorylation of the retinoblastoma susceptibility gene product in cycling and noncycling human hematopoietic cells.

Yusuke Furukawa; James A. DeCaprio; Arnold S. Freedman; Yuzuru Kanakura; Mitsuru Nakamura; Timothy J. Ernst; David M. Livingston; James D. Griffin


Experimental Hematology | 1994

Factor independence of human myeloid leukemia cell lines is associated with increased phosphorylation of the proto-oncogene Raf-1

Keiko Okuda; Ursula A. Matulonis; Ravi Salgia; Yuzuru Kanakura; Brian J. Druker; James D. Griffin


Blood | 1991

Granulocyte-Macrophage Colony-Stimulating Factor and Interleukin-3 Induce Rapid Phosphorylation and Activation of the Proto-Oncogene Raf-1 in a Human Factor-Dependent Myeloid Cell Line

Yuzuru Kanakura; Brian J. Druker; Kenneth Wood; Harvey J. Mamon; Keiko Okuda; Thomas M. Roberts; James D. Griffin


Stem Cells | 1990

The biology of GM‐CSF: Regulation of production and interaction with its receptor

James D. Griffin; Stephen A. Cannistra; George D. Demetri; Timothy J. Ernst; Yuzuru Kanakura; Richard Sullivan


Journal of Biological Chemistry | 1991

Phorbol 12-Myristate 13-Acetate Inhibits Granulocyte-Macrophage Colony Stimulating Factor-induced Protein Tyrosine Phosphorylation in a Human Factor-dependent Hematopoietic Cell Line*

Yuzuru Kanakura; Brian J. Druker; Jennifer DiCarlo; Stephen A. Cannistra; James D. Griffin


Blood | 1991

Identification of functionally distinct domains of human granulocyte- macrophage colony-stimulating factor using monoclonal antibodies

Yuzuru Kanakura; Stephen A. Cannistra; Cb Brown; Mitsuru Nakamura; Gf Seelig; Ww Prosise; Jc Hawkins; James D. Griffin

Collaboration


Dive into the Yuzuru Kanakura's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Stephen A. Cannistra

Beth Israel Deaconess Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Keiko Okuda

Kyoto Prefectural University of Medicine

View shared research outputs
Top Co-Authors

Avatar

Mitsuru Nakamura

Jikei University School of Medicine

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge